Objective-Myocardin, a potent transcriptional coactivator of serum response factor, is involved in vascular development and promotes a contractile smooth muscle phenotype. Myocardin levels are reduced during vascular injury, in association with phenotypic switching of smooth muscle cells (SMCs). However, the direct role of myocardin in vascular disease is unclear. Approach and Results-We show that re-expression of myocardin prevents the vascular injury response in murine carotid arteries, with reduced neointima formation due to decreased SMC migration and proliferation. Myocardin reduced SMC migration by downregulating platelet-derived growth factor receptor-β (PDGFRB) expression. Pdgfrb was regulated by myocardin-induced miR-24 and miR-29a expression, and antagonizing these microRNAs restored SMC migration. Furthermore, using miR-24 and miR-29a mimics, we demonstrated that miR-29a directly regulates Pdgfrb expression at the 3′ untranslated region while miR-24 has an indirect effect on Pdgfrb levels. Myocardin heterozygous-null mice showed an augmented neointima formation with increased SMC migration and proliferation, demonstrating that endogenous levels of myocardin are a critical regulator of vessel injury responses. Conclusions-Our results extend the function of myocardin from a developmental role to a pivotal regulator of SMC phenotype in response to injury, and this transcriptional coactivator may be an attractive target for novel therapeutic strategies in vascular disease. (Arterioscler Thromb Vasc Biol. 2013;33:2355-2365.)
O ne of the principal roles of a mature vascular smooth muscle cell (SMC) is contraction. SMCs in adult arteries have extremely low rates of proliferation and express a characteristic set of contractile proteins. 1 However, unlike cardiac or skeletal muscle cells, adult SMCs retain the plasticity to undergo a reversible phenotypic switch to an immature form, characterized by downregulation of the contractile apparatus, and higher rates of migration, proliferation, and deposition of extracellular matrix. 1 Phenotypic switching of SMCs is associated with vascular injury or disease responses, for example in restenosis after angioplasty, atherosclerosis, and accelerated graft disease. Although SMC plasticity is important for vessel repair after injury, it may also predispose to the development and progression of vascular disease. 2 Thus, understanding the molecular mechanisms that control SMC differentiation in disease may lead to novel approaches to treatment.
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Mature SMCs are characterized by expression of a range of SM-specific contractile proteins, including SM α-actin, SM myosin light chain kinase, SM myosin heavy chain, SM22α, smoothelin, and h1-calponin. The transcription of most SMC marker genes is regulated by serum response factor (SRF) binding to a cis-acting DNA sequence known as a CArG box (CC[A/T] 6 GG). Myocardin is a potent coactivator of SRF found only in smooth and cardiac muscle and regulates gene expression by forming a higher order complex with SRF rather than binding directly to DNA. [3] [4] [5] [6] Mice with homozygous null mutations for myocardin die during early aortic development and embryos fail to express SMC markers, whereas cardiac development seems normal. 7 However, myocardin is not absolutely required for SMC development, as homozygous myocardinnull embryonic stem cells can differentiate into SMCs in vitro, and in vivo these myocardin-null cells contribute to vascular smooth muscle in tissues, albeit to a lesser extent than wild-type cells. 8, 9 Loss of myocardin might, in part, be compensated for by the myocardin-related transcriptional factors (megakaryoblastic leukemia 1 [MKL1]) and (MKL2). 10 Apart from inducing SMC differentiation, myocardin has been reported to inhibit cell proliferation, 4 possibly by its interaction with nuclear factor (NF)-κB and suppression of NF-κB transcriptional activity. 11 Myocardin expression is associated with a contractile SMC phenotype, with reduced expression or function during phenotypic switching in vitro. For example, platelet-derived growth October 2013 factor (PDGF)-BB represses myocardin-induced SMC marker expression through a variety of mechanisms including Kruppellike factor 4-mediated inhibition of myocardin expression and function. 12 Despite extensive studies in culture, our understanding of the role of myocardin in SMC phenotypic switching and the injury response in vivo is significantly limited because only correlative data have been reported from animal models. For example, we have previously shown that myocardin decreases soon after carotid artery injury, in parallel with reduced SMC marker gene expression, 13 while others have recently documented similar reductions after coronary angioplasty 14 and femoral artery wire injury. 15 Critically, there is no direct evidence for the role of myocardin in SMC phenotypic switching in the injury response in vivo. Here, we present for the first time, data from myocardin gain and loss of function in mouse models of arterial injury and remodeling. We demonstrate that myocardin decreases neointima formation by reducing both SMC migration and proliferation. We identify a previously unknown role for myocardin as a regulator of SMC migration by inducing specific microRNAs (miR-24 and miR-29a) that downregulate PDGF receptor β (PDGFRB) expression. Conversely, reduced myocardin augments neointima formation in myocardin heterozygous-null mice. These studies demonstrate conclusively that modulating myocardin levels in vivo has a direct effect on the vascular injury response, and this may represent a new approach for the treatment of vascular diseases.
Materials and Methods
Detailed Materials and Methods are available in the online-only Supplement.
Mouse Model of Carotid Artery Wire Injury
Transluminal arterial injury was induced as previously described 16 in apolipoprotein E-deficient mice (C57BL/6 background). Immediately after wire injury, the left common carotid artery was cannulated, and the biclamped segment incubated with adenoviruses encoding myocardin or LacZ for 20 minutes. After 28 days, animals were euthanized, pressure-perfused with 10% formalin, and vessels embedded in paraffin for morphometric and histological analysis. Experiments were performed in compliance with the University of Leiden and Dutch government guidelines.
Mouse Model of Carotid Artery Ligation
Left common carotid artery ligation was performed on myocardin heterozygous-null 129/C57BL/6 mixed background male mice (obtained from Prof Eric Olson's laboratory) 7 and wild-type male littermates. Mice were euthanized 14 days postsurgery and pressureperfused with 10% formalin. These experiments were performed under UK Home Office licensing.
Cell Culture and Adenovirus Infection
Aortic vascular SMCs isolated from Wistar rats were maintained in 1:1 DMEM/F-12 medium supplemented with penicillin, streptomycin, L-glutamine, and fetal bovine serum. Cells were serum starved for 24 hours before in vitro experiments. Adenovirus vectors for LacZ and FLAG-tagged myocardin were purchased from the Gene Transfer Vector Core, University of Iowa.
Statistical Analysis
Data are presented as mean±SEM. Data were analyzed using a 2-tailed Student t test or using a 1-way ANOVA and Bonferroni test and were accepted as significant when P<0.05. All statistical tests were performed using GraphPad Prism (GraphPad Software, San Diego, CA).
Results

Loss of Myocardin Expression in Arterial Injury or Atherosclerosis
Previous studies have shown that SMC markers such as SM α-actin (Acta2), SM myosin heavy chain (Myh11), and myocardin are reduced after balloon injury to rat carotid arteries. 13 To validate that myocardin is also reduced in a murine model, we examined RNA from wire-injured murine carotids. Myocardin mRNA was significantly decreased within 1 week of wire injury (P<0.01; Figure 1A ). The decrease in myocardin levels also correlated with significant downregulation of Acta2 and Myh11 ( Figure 1B ). Together with previous studies on vascular injury, [13] [14] [15] these data suggest that loss of myocardin expression is an early and consistent feature of vascular pathology.
Expression of Myocardin Inhibits Neointima Formation After Vascular Injury
To investigate the role of myocardin after vascular injury, we re-expressed myocardin using adenovirus (Ad.)-mediated gene transfer. Mice underwent carotid wire injury followed by intraluminal instillation with adenoviruses. To ensure optimal transduction, we first examined efficiency in vivo using an Ad.LacZ virus. Efficient transduction was confirmed throughout the media using virus at 1.5×10 10 pfu/mL incubated intraluminally for 20 minutes ( Figure IA Ad.Myocardin also decreased medial area by 52% (P<0.001) but did not alter medial cell number suggesting that myocardin affected medial remodeling either through an effect on cell size or extracellular matrix deposition ( Figure 1F and 1G).
Vascular SMC (VSMC) proliferation and migration across the internal elastic lamina are key processes in neointima formation after vascular injury. To quantify proliferation and migration, mice received bromodeoxyuridine (BrdU) continuously throughout the postinjury period. Any BrdU-positive cell must have undergone proliferation after wire injury. Migration is harder to measure directly. However, as previously described, 17 we reasoned that because mice do not normally have intimal SMCs, then any BrdU-negative SMCs in the neointima must have migrated there from the media or transluminally and were classified as migratory cells. Clearly a cell could migrate into the neointima and then proliferate, in which case we would be underestimating the number of migratory cells. We used high-resolution confocal microscopy and ACTA2 expression to identify SMCs and to colocalize with BrdU ( Figure 2A ). Ad.Myocardin reduced neointimal ACTA2 positive cells by 47% (P<0.01), with no change in the number of medial SMCs ( Figure 2B and 2C). As predicted by previous in vitro studies, 4, 11, 18 Ad.Myocardin reduced cell proliferation in both neointima and media (P<0.05; Figure 2D and 2E). Importantly, Ad.Myocardin significantly reduced the number of BrdU-negative SMCs in the neointima (P<0.01) with no change in the media, indicating a novel role for myocardin in inhibiting SMC migration into the neointima ( Figure  2F and 2G).
Myocardin Attenuates PDGF-BB-Induced SMC Migration by Downregulating PDGFRB Expression
To determine the mechanisms responsible for myocardinmediated reduction in SMC migration, which has not previously been described, we performed in vitro experiments on cultured vascular SMCs. As SMCs undergo phenotypic modulation when placed in culture, and therefore express low levels of SM-contractile genes and myocardin, we performed gain of function studies using Ad.Myocardin, which led to detectable levels of myocardin in cultured SMCs ( Figure IIIA in the online-only Data Supplement). To assess cell migration, we used a chemotaxis assay using transwell inserts coated with matrigel to simulate the in vivo basement membrane in the vessel media. Ad.Myocardin reduced PDGF-BB-induced migration by 36% compared with Ad.LacZ treated cells (P<0.01; Figure 3A ). Ad.Myocardin also attenuated PDGF-BB-induced migration by 75% in a scratch assay model (P<0.001; Figure IIIB and IIIC in the online-only Data Supplement). PDGF-BB is known to activate PDGFRB and regulate SMC migration, proliferation, and cell survival during vascular injury. 19, 20 We, therefore, examined whether myocardin regulated PDGFRBB levels. Ad.Myocardin treatment significantly decreased expression of PDGFRB at both mRNA and protein ( Figure 3B and 3C). In keeping with these findings in rat aortic SMCs, similar results were also obtained using human embryonic stem cell-derived SMCs 21 ( Figure IVA and IVB in the online-only Data Supplement). Taken together, these results suggest that myocardin attenuates PDGF-BBinduced SMC migration by downregulating PDGFRB.
Myocardin Regulates PDGFRB Expression Through miR-24 and miR-29a
We next examined the mechanism of reduction in PDGFRB expression by myocardin, focusing on microRNAs (miRNAs) targeting PDGFRB. miRNAs are an emerging class of noncoding RNA that regulate gene expression at the posttranscriptional level by degrading the target mRNAs or inhibiting their translation. 22 Indeed, previous studies have shown that miR-26a, miR-143, miR-145, and miR-221 control SMC phenotypic switching 23, 24 and miR-21, miR-143, and miR-145 also regulate SMC migration. 24, 25 We, therefore, investigated the expression pattern of these miRNA in myocardin-treated cells. Myocardin significantly upregulated miR-143 and miR-145 and downregulated miR-26a and miR-221; miR-21 levels did not change ( Figure VA in the online-only Data Supplement). Moreover, blocking miR-143 and miR-145 by antagomirs in myocardin-treated cells rescued SMC migration only in part (P<0.01; Figure VB in the online-only Data Supplement). Also, antagonizing miR-143 and miR-145 did not alter the inhibition of PDGFRB by myocardin ( Figure  VC in the online-only Data Supplement), suggesting that modulation of PDGFRB by myocardin proceeded through an alternative pathway. The transfection efficiency of antagomirs was confirmed by visual fluorescent microscopy (>50% of all cells; data not shown).
To identify potential miRNAs that regulate PDGFRB expression, we performed an in silico search using the online prediction algorithm from www.targetscan.org. The software identified Pdgfrb as a possible target for miR-9, mir-24, miR-29a, and miR-30. Indeed, miR-24 and mir-29a were significantly upregulated and miR-30c was downregulated in SMCs treated with Ad.Myocardin compared with control cells ( Figure 3D and Figure . Although consensus CArG and CArG-like boxes were previously detected at both miR-24 and miR-29a promoter regions, through which myocardin could possibly function, 26 there was poor conservation between mouse and rat. We, therefore, targeted promoter regions where there was at least partial interspecies conservation ( Figure VIA and Table III in the online-only Data Supplement). Using chromatin immunoprecipitation with antibodies against myocardin and SRF, we were not able to amplify miR-24/-29a products from myocardin-transduced SMC, despite effective enrichment of the Acta2 and that expression of miRs-24 and -29a was SRF-dependent. However, functionality of the putative CArG or CArG-like boxes in their promoters was not tested, and indeed the poor cross-species conservation of the CArG(-like) elements is consistent with our observation of a lack of cis-element function. These results indicate that myocardin is inducing miR-24 and miR-29a expression either indirectly or via a CArG-independent mechanism (Figure VI in the online-only Data Supplement). A previous study also identified an inhibitory interaction between myocardin and NF-κB. 11 However, inhibition of NF-κB activity using 6-amino-4-{4-phenoxyphenylethyl-amino}-quinazoline, a cell permeable inhibitor, did not replicate the effect of myocardin overexpression in the Ad.LacZ control group or enhance the blockade of SMC migration in the Ad.Myocd treatment group ( Figure VII in the online-only Data Supplement). Therefore, we concluded that myocardin did not modulate SMC migration by inhibition of the NF-κB pathway.
Antagomirs for miR-24 or miR-29a partially rescued PDGFRB inhibition by myocardin, with a complete recovery of PDGFRB at both mRNA and protein observed with a combination of anti-miR-24 and anti-miR-29a ( Figure 3E and 3F). To determine whether Pdgfrb is a direct target of myocardin-induced miR-24 and miR-29a, we cotransfected the SMCs with a firefly luciferase reporter constructs containing the full length rat Pdgfrb 3′ untranslated region (UTR) and antagomirs for miR-24 and miR-29a ( Figure VIIIA in the online-only Data Supplement). Ad.Myocardin expression in VSMCs repressed the 3′ UTR Pdgfrb luciferase activity by 50%, and blocking miR-24 and miR-29a rescued the myocardin-induced inhibition of luciferase activity, suggesting that myocardin-mediated miR-24 and miR-29a may bind directly to target RNA and inhibit PDGFRB expression ( Figure 3G ). Furthermore, inhibition of both miR-24 and miR-29a markedly enhanced the migration of Ad.Myocardin-treated VSMCs ( Figure 3H ).
To determine whether miR-24/-29a acted directly on the 3′Pdgfrb-UTR, we performed additional experiments with miR-24/29a mimics investigating the expression of Pdgfrb mRNA, activity at 3′Pdgfrb-UTR and SMC cell migration ( Figure VIII VIIIB-VIIID in the online-only Data Supplement). Further scrutiny revealed that although the miR-29a seed sequence was conserved among human, mouse, and rat, the 2 binding sites for miR-24 were different between human and mouse/rat ( Figure VIIIE in the online-only Data Supplement). Given the lack of effect of miR-24 on the 3′Pdgfrb-UTR and the lack of conservation of its seed sequence, we proceeded to mutate just the miR-29a binding site on rat Pdgfrb 3′UTR that abolished the action of myocardin ( Figure VIIIA in the online-only Data Supplement; Figure 3I ). It is noteworthy that combination of miR-24/-29a mimics further potentiated the inhibition of 3′Pdgfrb-UTR activity and SMC migration compared with the mimics alone ( Figure VIIIC and VIIID in the online-only Data Supplement). We, therefore, conclude that miR-29a acts directly on the Pdgfrb 3′UTR while miR-24 likely has an indirect effect on Pdgfrb mRNA. However, we speculate that cooperativity of miRNA binding at the Pdgfrb 3′UTR is seen in the presence of miR-29a, leading to a direct effect by miR-24 and synergistic effects on the luciferase assay.
To corroborate that myocardin also worked through miR-24 and miR-29a in vivo, we measured the expression of miR-24 and miR-29a in a murine vascular injury model. Mice underwent carotid wire injury followed by intraluminal administration of either Ad.LacZ or Ad.Myocardin. Due to the minimal amounts of RNA that can be extracted from the injured segment of a single mouse carotid artery, it was necessary to pool 5 vessels per group before RNA extraction. Results, therefore, represent the mean of 5 vessels, but error bars and statistics cannot be applied because the samples were pooled. Vascular injury by itself (Ad.LacZ control groups) caused a profound reduction of miR-24, miR-29a, miR-143, and miR-145 in the injured vessel compared with its uninjured contralateral control ( Figure 3J and 3K and Figure IXA 
Myocardin Deficiency Potentiates Neointima Formation
The studies above have used a gain of function approach to show that re-expressing myocardin can inhibit both the SMC migration and proliferation associated with the vascular injury response. However, this does not prove that endogenous levels of myocardin directly inhibit these processes in vivo. We, therefore, examined myocardin +/− mice, which we established have lower myocardin expression in the aorta but similar levels of Mkl1 and Mkl2 compared with their wild-type littermates ( Figure X in the online-only Data Supplement). To more closely study the effects of low levels of myocardin on VSMCs, these experiments were performed after carotid artery ligation, a model with reduced complexity compared with atherosclerosis models. We also chose a time point of 14 days, when the neointima is not fully formed, to be able to determine any increase in neointima formation.
Neointimal area (3-fold increase; P<0.01) and total neointimal cell number were significantly increased in myocardin +/− mice 14 days after ligation compared with wild-type littermates ( Figure 4A -4C and Figure XI in the online-only Data Supplement). In myocardin +/− mice, the medial area was also increased by 30% (P<0.01) but medial cell numbers were unchanged ( Figure 4D and 4E ). Neointimal lesions from both myocardin +/− and wild-type mice contained mainly SMCs, staining positive for ACTA2 ( Figure 5A ), and SMC number was significantly higher in myocardin +/− mouse neointima with no changes in medial SMC number ( Figure 5B and 5C ). Myocardin +/− mice had significantly increased SMC proliferation in both neointima and media ( Figure 5D and 5E) and increased migrating (BrdU-negative) neointimal SMCs (P<0.01) with no alteration in medial nonproliferative BrdU-negative SMCs ( Figure 5F and To investigate the effect of reduced myocardin on PDGFRB, miR-24 and miR-29a expression, carotids from myocardin +/− mice and wild-type littermate controls were harvested 2 days postligation. miRNAs in injured vessels were normalized to expression levels in contralateral uninjured vessels. After carotid ligation, there was enhanced downregulation of myocardin mRNA levels in myocardin +/− mice compared with their wild-type littermates ( Figure 6A ). Additionally, greater reduction of miR-24 and miR-29a (by 50%, P<0.05; Figure 6B and 6C) and miR-143 and miR-145 (by 70% P<0.01; Figure XIII in the online-only Data Supplement) were observed in myocardin +/− mice compared with their wild-type littermates. Finally, we demonstrated that myocardin +/− mice have higher expression of PDGFRB in the neointimal SMCs with no changes in medial PDGFRB expression compared with the wild-type littermate controls ( Figure 6D-6F) . These loss of function in vivo studies are consistent with the virally mediated gain of function experiments and strongly suggest that endogenous levels of myocardin regulate neointima formation by decreasing both the migration and proliferation of VSMCs.
Discussion
Vascular SMCs respond to injury or disease by undergoing phenotypic switching and display a range of characteristic features including enhanced migration, proliferation, and deposition of extracellular matrix. 1 Extensive in vitro studies and developmental models suggest that myocardin has a central role in regulating SMC phenotype and SMC-specific gene expression through its interaction with SRF. However, there are very limited data on the role of myocardin in vascular injury or disease. Previous studies have reported a reduction of myocardin in association with the loss of SMC contractile gene expression. [13] [14] [15] However, these data are correlative only and there is no direct evidence that the loss of myocardin is causal in the vascular injury response in vivo. Moreover, the mechanisms by which myocardin might regulate this response are unclear.
We present here the first in vivo studies on the effects of gain and loss of myocardin on the neointimal response in injured and remodeling vessels. We show that myocardin regulates neointima formation after vascular injury through effects on SMC proliferation and a previously undescribed effect on SMC migration. The following novel observations support this conclusion: (1) ectopic expression of myocardin in a murine carotid artery injury model decreased neointimal formation by reducing both SMC migration and proliferation; (2) myocardin +/− mice had reduced levels of myocardin expression and displayed augmented neointima formation due to increased SMC migration and proliferation; (3) myocardin reduced PDGFRB expression in cultured VSMCs whereas myocardin +/− mice exhibited increased PDGFRB expression in the neointima; and (4) the inhibitory effects of myocardin on SMC migration and PDGFRB expression were mediated, in part, through miR-24 and miR-29a. Based on these findings, we propose that endogenous levels of myocardin have a key role in regulating SMC phenotype in vivo, and expression or activity of this transcription factor are key determinants of the vascular injury response. Moreover, we outline a novel molecular mechanism involving miR-24 and miR-29a that underlies, in part, the action of myocardin in vascular disease.
Myocardin-Mediated Modulation of Proliferation and Migration In Vivo
We identify that myocardin repression is a key requirement for the development of vascular disease and that modulation of myocardin levels and activity regulate the injury or disease response. After arterial injury, medial SMCs undergo proliferation or migration or both and synthesize extracellular matrix, resulting in neointima formation. 27 Although it has been suggested that bone marrow-derived SMC-like cells may also colonize the neointima after vascular injury, such cells represent a very small fraction of the total neointimal cells, 17 and high-resolution confocal studies have shown that most neointimal SMCs are derived from the vessel wall. 28 Myocardin has previously been shown to regulate negatively SMC proliferation in vitro, 4, 18 possibly through an interaction with NF-κB. 11 We extend these findings using 2 distinct animal models to show that myocardin similarly regulates SMC proliferation and the neointimal response in vivo. Moreover, we demonstrate, to our knowledge for the first time, that myocardin also regulates SMC migration, both in vitro and in vivo, in both a simple flow cessation model and a more complex wire injury/atherosclerosis model. To summarize, we have identified myocardin as a key regulator of the vascular injury response that modulates multiple aspects of SMC phenotypic switching including proliferation and migration, leading to the development of a neointimal lesion.
Modulation of PDGF-BB Pathway by Myocardin and miRNAs
In this study, myocardin inhibited PDGF-BB-induced smooth muscle migration by downregulating the expression of PDGFRB. A previous study has demonstrated that forkhead box protein O4 binding represses the activity of myocardin and prevents SMC differentiation. 29 On stimulation of the phosphatidylinositol 3'-kinase/Akt pathway, which may be activated by PDGF signaling, forkhead box protein O4 was exported from the nucleus resulting in activation of myocardin. However, in other studies, myocardin was inhibited by PDGF-BB signaling via Kruppel-like factor 4 12 or ETS-like gene 1. 30 Combining these observations with our results, we propose an autoregulatory model whereby myocardin is either activated or inhibited by PDGF-BB signaling in a context-dependent manner and in turn regulate PDGF-BB activity through miR-24 and miR-29a. Such context dependency may explain why PDGF-BB has repressive effects on SMC gene expression in mature SMCs while stimulating SMC gene expression and differentiation in SMC progenitors. 21, 31, 32 Interestingly, Chan et al 33 recently showed that miR-24 was upregulated by PDGF-BB and was required for the inhibition of the bone morphogenetic protein-induced contractile phenotype. This apparent discrepancy with our results in which myocardin inhibits PDGFRB and SMC migration in part through miR-24 may also be because of context-dependent effects. Another explanation may be the use of pulmonary artery SMCs by Chan et al, 33, 34 which may differ in their response to the aortic SMCs we used. Finally, although miR-24 inhibits bone morphogenetic protein signaling through potentiation of Smurf1 activity, the interaction of Smurf1 with other contractile pathways such as transforming growth factor-β and myocardin is less well defined. Therefore, miR-24 should not be considered as a general effector of phenotypic switching by PDGF-BB, on the basis of the studies by Chan et al 33 that apply principally to bone morphogenetic protein signaling. Indeed, miR-24 may comprise part of the complex feedback mechanisms that result in the context-dependent effects of PDGF-BB.
MicroRNAs are highly conserved, 22-nucleotide noncoding RNAs that regulate diverse cellular functions through the repression of target genes during development and in disease. 35 Several recent studies have identified the expression of miRNAs in the vasculature and their involvement in regulating SMC function and phenotypic modulation. 24, 36 Of these, miR-143 and miR-145 are well studied in SMC differentiation. Indeed, miR-143 and miR-145 are direct transcriptional targets of myocardin and are downregulated during vascular injury and atherosclerosis. 23 In the present study, we also observed that myocardin induced the expression of both miR-143 and miR-145 ( Figure VA in the online-only Data Supplement). In addition, antagonizing miR-143 and miR-145 partially rescued SMC migration in the presence of myocardin ( Figure VB in the online-only Data Supplement). These data are consistent with previous observations whereby downregulation of miR-143 and miR-145 induced the formation of podosomes and migration of SMCs. 25 We initially speculated that miR-143 and miR-145 were responsible for the repression of PDGFRB expression. However, although miR-143 and miR-145 did contribute, in part, to inhibition of SMC migration by myocardin, there was another pathway that regulated PDGFRB ( Figure VC in the online-only Data Supplement).
Using a bioinformatics approach to narrow down the potential miRNAs that may regulate PDGFRB, we identified miR-24 and miR-29a. miR-24 overexpression has previously been shown to lead to cardiomyocyte hypertrophy and is also linked to both cardiomyocyte and endothelial cell apoptosis and angiogenesis. [37] [38] [39] The miR-29 family has been known to promote fibrosis by regulating a number of collagen isoforms, fibrillins, and elastin in liver, heart, and aorta. [40] [41] [42] PDGF-BB is also known to induce miR-24 and control the synthetic phenotype in SMCs 33 while, consistent with our findings, miR-24 and miR-29a have been reported to be downregulated after vascular injury 43 in parallel with the downregulation of myocardin. However, to our knowledge, this is the first report that miR-24 and miR-29a have a role in the regulation of SMC migration.
Validation of Mechanisms In Vivo
These and other studies [13] [14] [15] confirm that myocardin expression is reduced in cultured SMCs or after vascular injury. In vitro, we present considerable evidence that re-expression of myocardin inhibits SMC migration at least, in part, through miR-24-mediated and miR-29a-mediated inhibition of PDGFRB. In vivo we were also able to confirm myocardin transgene expression in the Ad.Myocardin group by the presence of the FLAG tag on Western blotting. Interestingly, myocardin mRNA and expression of SMC markers were only increased moderately in the Ad.Myocardin-treated vessels compared with Ad.LacZ controls ( Figure I in the online-only Data Supplement), whereas Pdgfrb showed only a small reduction ( Figure IXB in the onlineonly Data Supplement). These modest changes, although consistent with the mechanism identified in vitro, were in contrast to the large changes detected in level of miR-24 and miR-29a with Ad.Myocardin treatment. It is possible that there may be a relatively low threshold above which myocardin is able to inhibit the injury response which even a modest increase in myocardin expression in the Ad.Myocardin group is able to reach. The adventitia may also have contributed to the background reducing our ability to discriminate differences in expression between the Ad.LacZ and Ad.Myocardin groups at 3 days postinjury. In addition, there may be further increases in myocardin expression level in the Ad.Myocardin group at later time points to mitigate the profound reduction seen at 1 week in nontransduced injured vessels ( Figure 1A ). Finally, it is possible that the differences in PDGFRB expression between in vitro and in vivo studies reflect differences in mode of action of the miRNAs. Recent studies suggest that miRNA-mediated gene silencing operates through multiple mechanisms including a combination of mRNA decay and translational repression, and different elements may predominate in different settings. 44, 45 Further studies involving the delivery of miR-24 and miR-29a to overcome the increased development of neointima in the Myocd +/− mice could be performed to further test our proposed mechanism in vivo.
In conclusion, using a series of in vivo gain and loss of function studies and in vitro mechanistic studies, we have identified that myocardin is a key regulator of the neointimal response. This includes a previously unidentified role in regulating VSMC migration, via a novel mechanism involving induction of miR-24 and miR-29a and inhibition of the PDGFRB pathway ( Figure 6G ). We propose that, in addition to its well-documented developmental role, myocardin is a vital regulator of smooth muscle phenotype in response to pathological stimuli. The profound effects of myocardin on the vascular response to injury suggest that this transcriptional coactivator may be an attractive target for novel therapeutic strategies in vascular disease.
Myocardin is a smooth muscle cell and cardiomyocyte restricted transcriptional coactivator, principally known for its role in smooth muscle cell development and gene expression. Although myocardin expression decreases in phenotypically modulated smooth muscle cells, there are no studies demonstrating a direct causal role for myocardin in the vascular injury response. Here, we have performed both gain and loss of myocardin function experiments in vivo, and we report for the first time that myocardin has a direct role in the vascular injury response. We identify a previously unknown role for myocardin in the regulation of smooth muscle cell migration and delineate a novel molecular mechanism involving miR-24 and miR-29a by which myocardin regulates platelet-derived growth factor receptor β and cell migration. The clinical significance of our findings is that the myocardin level seems to be a pivotal regulator of the vascular injury response, and myocardin or associated microRNAs may be attractive targets for novel therapeutic strategies in vascular disease.
Significance
